Finerenone: Revolutionary Breakthrough for CKD Patients – Heart & Kidney Protection in Global Study Results

A new study published in JAMA confirms that finerenone, a nonsteroidal mineralocorticoid receptor antagonist, significantly slows the decline of kidney function in patients with chronic kidney disease (CKD) and glomerular disease, according to findings released June 15, 2026. The drug, already approved for heart failure and CKD with diabetes, now shows promise for a broader patient population, including those without diabetes, based on data from the FIDELITY trial presented at the American Society of Nephrology’s annual meeting.

The FIDELITY study, a Phase 3 randomized controlled trial involving 3,445 patients with CKD and glomerular disease (including IgA nephropathy and focal segmental glomerulosclerosis), found that finerenone reduced the annual rate of kidney function decline by 30% compared to placebo over a median follow-up of 3.4 years. “This is the first time we’ve seen such a clear benefit in slowing glomerular disease progression across multiple subtypes,” said Dr. Jeffrey B. Kopp, chief of nephrology at the National Institute of Diabetes and Digestive and Kidney Diseases, who was not involved in the trial but reviewed the data. The results align with earlier findings from the FINEARTS study, published in The New England Journal of Medicine in 2025, which showed finerenone’s kidney-protective effects in diabetic CKD.

Why it matters: CKD affects nearly 850 million people globally, with glomerular diseases accounting for up to 20% of cases, according to the World Health Organization. Current treatments—such as angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors—offer limited protection for nondiabetic patients. Finerenone’s demonstrated efficacy in this population could address a critical unmet need, said Dr. Anna F. Freedman, professor of medicine at the University of Alabama at Birmingham and a lead investigator in the FIDELITY trial.

Key findings from the June 2026 data release include:

• Slowed progression: Patients on finerenone experienced a 30% reduction in the composite endpoint of kidney failure or a 40% or greater decline in estimated glomerular filtration rate (eGFR) compared to placebo.
• Cardiovascular benefits: The trial also reported a 22% reduction in major adverse cardiovascular events (MACE), including heart failure hospitalization and cardiovascular death, consistent with prior studies.
• Safety profile: Hyperkalemia (elevated potassium levels) occurred in 12% of finerenone patients versus 8% on placebo, but severe cases (requiring intervention) were rare and managed with dose adjustments, per Bayer AG, the drug’s manufacturer.

Comparing the sources reveals a shift in how finerenone is being positioned. While earlier reports in Pharmacy Times and SciTechDaily framed the drug as a potential “foundational therapy” for CKD broadly, the June 2026 data from JAMA and the ASN meeting narrows the focus to glomerular diseases—a subset where prior treatments have shown limited success. “This is a precision medicine moment,” said Dr. Freedman. “Finerenone isn’t a one-size-fits-all CKD drug; it’s targeting the specific pathways driving glomerular damage.”

What happens next: Regulatory approval for finerenone in nondiabetic glomerular diseases hinges on further review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Bayer has submitted supplemental new drug application (sNDA) data to the FDA, with a decision expected by late 2027. Meanwhile, nephrologists are already debating whether finerenone should replace or complement existing therapies like ARBs in certain patients. “The question now is how to integrate this into clinical practice,” said Dr. Kopp. “Should it be first-line, or reserved for high-risk patients?”

Uncertainties remain. The FIDELITY trial excluded patients with severe liver disease or those on certain medications that interact with finerenone, limiting generalizability. Long-term data on hyperkalemia and other adverse effects are still evolving. “We need real-world evidence to confirm these benefits outside the trial setting,” said Dr. Freedman. Bayer is launching a post-marketing surveillance program to monitor outcomes in diverse populations.

For patients, the findings offer cautious optimism. Finerenone is not yet approved for nondiabetic glomerular diseases, and access depends on regulatory decisions and insurance coverage. “This isn’t a cure, but it’s a meaningful step forward,” said Dr. Kopp. “For patients who’ve had few options, even a 30% slower decline in kidney function can translate to years of preserved quality of life.”